Sage Therapeutics posted phase 2 results from its Parkinson’s disease study yesterday in which it said its experimental med could help tremors, but the top-line data were met with confusion by Bio ...

The first wave of atmospheric data from the Stratospheric Aerosol and Gas Experiment III (SAGE III), a NASA instrument that launched to the International Space Station earlier this year, is now ...

Sage, provider of cloud business management solutions, is releasing its new, cloud-first Sage Data and Analytics service integration for Sage 300 and Sage 100 in the U.S. and Canada. A powerful ...

Sage Therapeutics has scored another big win in the clinic. SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder (MDD), sending its stock on a tear ...

Imagine you run R&D for a major software firm. Your employer has grown the company massively over the last couple of decades with acquisitions of competing and complementary product lines. You now ...

Sage Therapeutics, Inc. (SAGE) stock remains a hold for now. The reason why I think this stock should be a "hold" rating is because it expects to report results from its phase 2b KINETIC 2 Study, ...

Sage has introduced a data and analytics product in the U.S. and Canada built around its Sage 100 and 300 accounting software. Processing Content Sage Data & Analytics (SD&A) is a business ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive ...

Sage integrates the AI assistant Copilot into its ERP software Sage Operations. It is intended to enable better control of ...

– Now Also Available on Oracle Exadata Database Machine, OptimizedArchitecture of Sage ERP X3 and Oracle Database 11g Combine to Offer GreaterPerformance ...